- Celldex Therapeutics (CLDX -2.7%) is out with results from a preclinical study of a CDX-301/ Mozobil combo.
- The company says that in combination, the agents "significantly increased hematopoietic stem cell mobilization in mice [supporting] future clinical development of CDX-301 and demonstrat[ing] a novel potent cell mobilization regimen."
- In easier to understand terms: "...this regimen could improve stem cell transplantation outcomes for patients across a broad range of indications." (PR)
Celldex Therapeutics reports data from preclinical combo study
Dec 10 2013, 14:57 ET